What it takes: Getting a HIV vaccine in our lifetime(s)

What it takes: Getting a HIV vaccine in our lifetime(s)

What it takes: Getting a HIV vaccine in our lifetime(s)

By Dázon Dixon Diallo, DHL MPH

Some might say 37 years is long enough. They might think that within nearly four decades we should have found a way to globally vaccinate against one of the most elusive, smart and resilient viruses in the history of public health. I would say, Is that so? Why would you think that?

From the earliest days of the AIDS epidemic, scientists, clinicians and community activists have been working, most often together, and sometimes not, on the pursuit of an effective vaccine that would essentially end the HIV pandemic, and provide a universal prevention intervention for generations to come.

In that time, we have benefitted from the advances in HIV treatment and prevention science, with the advent of Treatment as Prevention, Pre-exposure Prophylaxis (PrEP), Perinatal Transmission Prevention and subsequent successes with co-morbidities like Hepatitis C and some cancers. Despite these incredible advances in treatment and prevention, we still need a vaccine.

We have witnessed the effects of providing comprehensive information, services and supports that enable people to prevent HIV, to live well with HIV and to help others get into care early in their diagnosis – and we still need a vaccine.

We have charged and changed governments to make better policy and implement progressive social change to eliminate some of the barriers to treatment, care and prevention – and we still need a vaccine.

The start and stop progress that has defined the field of HIV Vaccine research has been consistently rescued by hope – the hope of scientists that they can find the right molecules, the hope of communities of advocates and activists that our fight will one day end, and the hope of millions of people living with HIV that their struggles to surmount stigma and to live in dignity will win the day.

We all owe debts of gratitude to our brothers, sisters and comrades on the African Continent.

As much as we have engaged communities to increase research literacy in order to engage more effectively with the science, we have a long way to go to engage researchers to increase community literacy in order to more effectively design trials and tools that have value and meaning to folks who need them the most.

On this HIV Vaccine Awareness Day, as an activist who has been in this fight for 33 years, I am giving honor and thanks to the tens of thousands of people, especially the African souls who have put their bodies and their lives on the line to find the vaccine that will work for billions around the world. Without the involvement of people who are carrying the overwhelming burden of the epidemic, we would have never gotten this far.

And with our eye on the prize of ending the epidemic as we know it, we must remain humble, respectful and stand in solidarity with African peoples as they lead us through the next stages of advancement and discovery in HIV Vaccine Research.

For me, this and every HIV Vaccine Awareness Day belongs to those research participants, and to all of the researchers who have learned how to build solidarity and respect the critical, indispensable role of indigenous expertise, of the lived experience.

The Rastafarians have always said that “Africa awaits its creators”, meaning that Africa’s problems will be resolved with African solutions – by people of African Descent wherever they are. I embrace this belief as the ultimate hope for us all.

Diallo is Founder/President, SisterLove USA/RSA

Keep up with NHVMAS activities on our social media platforms and join the conversation

Facebook: www.facebook.com/nhvmas

Twitter: @nhv_mas

HIV Vaccine Awareness Day: A reflection

HIV Vaccine Awareness Day: A reflection

HIV Vaccine Awareness Day: A reflection

By Steve Wakefield

HIV Vaccine Trials Network, Seattle, WA, USA


Community responses in times of intense need are often the most effective agents for change. We have had the opportunity to witness the brilliant effect of human beings in action recently during several hurricanes and mass shootings in the US. Advocacy and change have been fueled by historical movements as well, such as the Boipaton massacre in South Africa that prompted local, and eventually global, efforts to end apartheid. Injustice and inhumanity, hate and oppression, have also sounded the clarion bell that demanded and demands unity, and encourages collective gathering for strength and sustained hope in the face of inequalities.

As we reflect on HIV Vaccine Awareness Day (HVAD), there are advances brought forward by medical science, as well as a continued need for communities to lead the charge for change. For HVAD, let us reflect for a moment on critical points in HIV’s history, while also considering how to increase our efforts, individually and collectively, to get us to an HIV vaccine.

Early in this epidemic community members took to the streets. Communities also gathered to share information about any scientific development which seemed hopeful or useful. ACT UP, TAC and other groups fought governments because they were not doing enough, or not doing it fast enough, or not doing it the right way.

Community responses brought a sense of passion and urgency to make a difference, processing grief and anger, or because many were afraid their own time might be short due to the mysterious virus. Scientists and providers frequently left their labs or the bedsides of their patients to join marches and demonstrations. Others worked hard from inside hallowed halls to quietly identify ways to accelerate change.

The ongoing debate regarding what is needed most in an HIV vaccine response, t-cells or antibodies, continues. HIV and research myths have continued to have validity despite an army of Community Advisory Board members and other advocates who immerse themselves in the science and can interpret trial results and progress.

Community emphasis on building and leveraging key partnerships to ensure stronger voices and policy support for HIV vaccine research has struggled side by side with an enhanced behavioral research agenda to support engagement in trials. Barriers to participation in HIV preventive vaccine studies have persisted, including historical mistrust of medical providers and research.

It may be easier for persons already diagnosed with an incurable illness (HIV) to participate in research than it is for healthy, uninfected persons who do not think of themselves as being at risk to join a study.

Vaccine study participants and communities of otherwise healthy individuals are asked to make personal sacrifices for the sake of research.  They must commit time, respond to invasive and personal questions, and potentially face criticism from their family, friends, and communities.  The vaccines they receive may not provide any level of protection nor offer any immediate or long-term benefits.

Many still hold on to unfounded myths such as “you can get HIV from a vaccine,” or wonder how researchers can test a vaccine without intentionally infecting people, while others say they believe a vaccine exists but is being kept secret.

Fostering trust and increased understanding of HVTN’s research begins with updates during potential study concept stages, with a goal of moving persons from community awareness of the scientific agenda through engagement during study planning, and community ownership throughout the time a study is being conducted.

With this in mind, HVTN community engagement partners are in regular contact with local community stakeholders, country level persons from multiple disciplines, and global HIV prevention stakeholders.

This time in the history of the HIV epidemic is bittersweet. There are exciting new tools for treatment and prevention, and funded cure research is occurring with remarkable attention across biomedical disciplines. Extraordinary advances in the treatment and prevention of HIV infection bring many to the conclusion that it is possible to end the HIV epidemic through scaling up these interventions.

At the same time, there is a lack of resources to provide for those at highest need, and a surge in stigma/discrimination. Politics are once again placing the lives of people in need on the back burner.

One new challenge is to be vigilant and hopeful while working with warriors who have been leading the charge. We must do this while developing the next generation of people who can exude unity, gathering for strength and sustained hope.

* S. Wakefield is the Director of External Relations for the HVTN. These thoughts and others originally appeared as a World AIDS Day Reflection in HVTN’s Community Compass.  Full article at:

http://www.hvtn.org/content/dam/hvtn/CommunityCompass/CommunityCompass-2017-Issue2-ENGLISH-Web.pdf

Keep up with NHVMAS activities on our social media platforms and join the conversation

Facebook: www.facebook.com/nhvmas

Twitter: @nhv_mas

#HVAD: Donors need to invest more on HIV vaccine -CRH

#HVAD: Donors need to invest more on HIV vaccine -CRH

#HVAD: Donors need to invest more on HIV vaccine -CRH

HVAD: STATEMENT FROM CRH

As the Centre for the Right to Health celebrates the HIV Vaccine Awareness Day, It urges that research for vaccines against other infectious diseases should not be left behind.

Vaccine has a great place in disease prevention. Over the decades, vaccination has again and again proved to be the most potent force in disease prevention and eradication. This is true for the worldwide eradication of smallpox and the control of diseases such as polio, measles, and tetanus from much of the world.

The effectiveness of vaccination has been widely studied and verified in the influenza vaccine; HPV vaccine and the chicken pox vaccine. The World Health Organization (WHO) reports that licensed vaccines are currently available for twenty-five different preventable infections.

On the occasion of the 2018 World Vaccine Awareness Day, Centre for the Right to Health (CRH) joins the New HIV Vaccine and Microbicide Advocacy Society (NHVMAS) and other Men of good conscience to salute all past, present and future researchers, bioethicist, community advocates, donors who have invested and continue to invest time and money in vaccine developments.

However, it is not yet over as HIV, Ebola, Lasser fever are still on the rampage. HIV has been with us for years and has had a great toll on human lives. We encourage donors and researchers to please continue to invest resources in finding a vaccine for this scourge. It is also important to invest resources to HIV prevention and education. The present roll back on investment in these areas would adversely affect the gains of yester-years.

Keep up with NHVMAS activities on our social media platforms and join the conversation

Facebook: www.facebook.com/nhvmas

Twitter: @nhv_mas

Vulnerable women and girls will benefit from a HIV Vaccine

Vulnerable women and girls will benefit from a HIV Vaccine

By Hajia Jamila Ibrahim – Yahaya (LDM Fellow)

I am a Counselling and Social Development Consultant, the Society for Women and AIDS in Africa, Nigerian Chapter (SWAAN), and author of the book, “When the Sexually Abused Child Demands Fair Hearing”. The book is the outcome of a study funded by Development Research And Project Centre (DRPC) and MacArthur Foundation in 2017 for a project, Partnership To Strengthen Innovations And Practice In Secondary Education (PSIPSE).

The study found out that the vulnerability of the out-of-school girl child to sexual abuse and HIV deserves better attention than it receives now.

I congratulate NHVMAS on this initiative of Festival of Blogs to amplify voices on their interest in HIV vaccine development to promote continued investment in HIV vaccine research.

Nigerian women and girls are no doubt among the key affected population for HIV and AIDS due to their very high vulnerability to HIV resulting from community level risks and individual level risks. Their vulnerability is independent of their socio-cultural or socioeconomic environment: they are at risk in all socio-cultural or socioeconomic context.

Some of the very vulnerable women and girls include the out-of-school girls; women and girls in incarceration and Internally Displaced Persons camps; women and girls with physical and mental challenges; juvenile delinquent children abusing drug and indulging in sex; teenage sex workers, trafficked women and girls or and sex slaves; and women and girls living with HIV that have not been reached.

All these categories of women and girls are vulnerable to HIV and would benefit immensely from research that helps develop an effective and cheap HIV VACCINE that can be accessible to everyone. There should be no barriers to access.

Institute of Human Virology joins the world to mark HIV Vaccine Awareness Day

IHVN: An effective HIV vaccine is needed in order to reduce new infections and reach the target of ending the global AIDS epidemic by the year 2030.

The Institute of Human Virology_Nigeria on the 2018 HIV Vaccine Awareness Day (HVAD)

The Institute of Human Virology Nigeria (IHVN) celebrates and acknowledges the role played by volunteers, support groups and other community members, health professionals, and scientists in the struggle to find a safe, practical, affordable and effective preventative HIV vaccine. Preventative vaccines when used appropriately have been found to be safe and more cost effective to prevent diseases than treatment, and they help save millions of lives. Therapeutic vaccines also slow down the progression of infection and eliminate the necessity for drug treatment.

Much more than ever, an effective HIV vaccine is needed in order to reduce new infections and reach the target of ending the global AIDS epidemic by the year 2030. This has been a major challenge to researchers for more than 30 years now due to the peculiarities of the virus.

IHVN supports the call for government assistance to on-going researches to understand how HIV infection is in the different populations of the country, as well as the steps towards an effective vaccine.

Signed:

Dr Patrick S. Dakum, MBBS, MPH, Dip (Theo),

Chief Executive Officer,

Institute of Human Virology, Nigeria (IHVN).

Keep up with NHVMAS activities on our social media platforms and join the conversation

Facebook: www.facebook.com/nhvmas

Twitter: @nhv_mas

HIV Vaccine Awareness Day: Thinking Key and Vulnerable Populations 

HIV Vaccine Awareness Day: Thinking Key and Vulnerable Populations   

To commemorate the 2018 HIV Vaccine Awareness Day which is marked May 18th every year, a group, Heartland Alliance International Nigeria (HAI), made a statement. POSTERITY MEDIA, in partnership with New HIV Vaccine and Microbicide Advocacy Society (NHVMAS) to commemorate the day, brings you the full statement as released: 

Press release from Heartland Alliance International Nigeria

Heartland Alliance International Nigeria (HAI) joins The New HIV Vaccine and Microbicide Advocacy Society (NHVMAS) and the world to commemorate the 20th anniversary of the HIV Vaccine Awareness Day (HVAD).

May 18 is HIV Vaccine Awareness Day—an opportunity to recognize the volunteers, community members, health professionals, and scientists involved in HIV vaccine research. It is also a time to educate about the importance of HIV vaccine research and urge the international community to recognize the importance of investing in new technologies as a critical element of a comprehensive response to the HIV/AIDS epidemic.

HAI works at the forefront of HIV prevention, treatment and care for key and vulnerable populations in Nigeria. With a national HIV prevalence rate of 3.17%, key populations are disproportionately affected, with men who have sex with men, female sex workers and people who inject drugs having prevalence rates of 22.9%, 19.4% and 3.4% respectively. Despite the increased use of treatment and prevention options, this on its own is unlikely to stop the HIV epidemic. As Bill Clinton rightly stated, “only a truly effective, preventive HIV vaccine can limit and eventually eliminate the threat of AIDS.”

As an organization committed to securing the rights and well-being of marginalized people and communities, we are committed on this day and indeed every day to international research that will one day end the AIDS epidemic. We therefore join hands with other HIV vaccine advocates to promote the continued urgent need for a vaccine to prevent HIV infection and AIDS.

This press release opens up the NHVMAS festival of blogs, which calls on all persons to share blogs on the NHVMAS website celebrating HIV vaccine research efforts until date, and sharing visions of what impact a HIV vaccine can have on global health, peace and development. The objective of this festival of blogs is to amplify all voices about their interest in HIV vaccine development, their expectations about the vaccine, and promote continued investment and HIV vaccine research.

Keep up with NHVMAS activities on our social media platforms and join the conversation

Facebook: www.facebook.com/nhvmas

Twitter: @nhv_mas